Patent Foramen Ovale Closure among Patients with Hypercoagulable States Maintained on Antithrombotic Therapy
- 12 February 2021
- journal article
- research article
- Published by S. Karger AG in Cardiology
- Vol. 146 (3), 375-383
- https://doi.org/10.1159/000512184
Abstract
Background: Percutaneous device closure was shown to effectively prevent recurrent strokes in patients with patent foramen ovale (PFO). Whether this protective effect is relevant for patients with hypercoagulable states (HCSs) is unknown as they were not represented in prior studies. Methods: Data on 136 consecutive patients with a PFO and clinically significant HCS were retrospectively collected. PFO closure and antithrombotic regimen were decided on an individual basis by the treating physicians, and adherence to therapy was routinely evaluated. The outcome was the occurrence of cerebrovascular accident (CVA) or transient ischemic attack (TIA). Results: HCS types consisted of antiphospholipid syndrome (31%), factor-5 Leiden mutation (22%), prothrombin mutation (18%), protein S deficiency (15%), protein C deficiency (7%), methyl-tetra-hydro folate reductase mutation (5%), and essential thrombocytosis (2%). 102 patients (75%) were maintained on anticoagulants and the remaining on antiplatelet therapy. PFO closure was undertaken in 85 (63%); antithrombotic therapy was not interrupted prior to or after the procedures. At a mean follow-up of 46 ± 8 months, 23 patients (17%; 95% confidence interval, 9.3–22%) experienced an outcome event, mainly in the form of CVAs (n = 15, 65%). In multivariable analysis, PFO closure was associated with a 5-fold decrease in the risk of CVA/TIA (p = 0.02). This effect was independent of the type of HCS or antithrombotic therapy. Conclusions: Among patients with HCSs maintained on anticoagulant or antiplatelet therapies, PFO closure was associated with a significantly lower risk of CVA or TIA.Keywords
This publication has 22 references indexed in Scilit:
- G1691A factor V and G20210A FII mutations, acute ischemic stroke of unknown cause, and patent foramen ovaleThrombosis Research, 2012
- Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen OvaleThe New England Journal of Medicine, 2012
- Perioperative Management of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Patent Foramen Ovale in Cryptogenic StrokeStroke, 2009
- Echocardiography-Guided InterventionsJournal of the American Society of Echocardiography, 2009
- Risk of Thromboembolism With Short-term Interruption of Warfarin TherapyArchives of Internal Medicine, 2008
- Prothrombotic Mutations as Risk Factors for Cryptogenic Ischemic Cerebrovascular Events in Young Subjects With Patent Foramen OvaleStroke, 2007
- Inherited ThrombophiliaCritical Reviews in Clinical Laboratory Sciences, 2006
- Prevalence of Patent Foramen Ovale in Patients with StrokeThe New England Journal of Medicine, 1988
- Incidence and Size of Patent Foramen Ovale During the First 10 Decades of Life: An Autopsy Study of 965 Normal HeartsMayo Clinic Proceedings, 1984